Previous 10 | Next 10 |
The FDA designates ProQR Therapeutics N.V.'s ( PRQR +2.3% ) QR-1123 for Fast Track review for the treatment of autosomal-dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin (RHO) gene. More news on: ProQR Therapeutics N.V., Healthcare stocks news, Stocks on the move...
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announc...
LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announce...
ProQR (NASDAQ: PRQR ): Q2 GAAP EPS of -€0.30. More news on: ProQR Therapeutics N.V., Earnings news and commentary, Healthcare stocks news, Read more ...
LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported...
ProQR Therapeutics (NASDAQ: PRQR ) announces that its sepofarsen (QR-110) drug candidate for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the PRIority MEdicines (PRIME) program by the European Medicines Agency (EMA). More news on: ProQR Therapeut...
Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval ProQR believes that the EU will represent...
Gainers : Tower International (NYSE: TOWR ) +69% . Camber Energy (NYSEMKT: CEI ) +50% . HOOKIPA Pharma (NASDAQ: HOOK ) +28% . Milacron Holdings (NYSE: MCRN ) +25% . VivoPower International PLC (NASDAQ: VVPR ) +21% . ProQR Therapeutics N.V. (NASDAQ: PRQR ) +21% . Oasmi...
ProQR Therapeutics N.V. ( PRQR +12.9% ) is up on slightly higher volume ahead of a presentation on candidate QR-421a in Usher syndrome tomorrow at the Annual Usher Connections Conference in Philadelphia. More news on: ProQR Therapeutics N.V., Healthcare stocks news, Stocks on the move,...
LEIDEN, Netherlands and CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced an upcoming presen...
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the An...
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA edi...
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully defended against opposition filed against a key pate...